HUTCHMED - News & Press Releases

2007 年9 月18 日，和黃醫藥與製藥巨頭美國禮來公司（簡稱“ 禮來” ）於上海浦東金茂君悅酒店隆重召開合作慶典儀式，正式宣布雙方在新藥研發領域建立戰略合作關係。這是中國藥物研�

TR-1: Notification of major interests in shares

Notice of Announcement of 2008 Final Results

Chi-Med Announces Completion of Patient Enrolment in its US Phase II Crohn's Disease Clinical Trial of HMPL-004, its Lead Anti-Inflammatory Drug Candidate

TR-1: Notification of major interests in shares

TR-1: Notification of major interests in shares

Holding in Company

Director's Shareholding

HMPL-002 Clinical Update

Blocklisting Six Monthly Return

和黃醫藥攜手強生旗下的Ortho-McNeil-Janssen製藥公司共同研究開發創新藥物

Director's Shareholding

和黃醫藥與美國禮來再度牽手

和黃醫藥榮獲2008美國胃腸病學會學術年會國際獎

Board Change

Interim Results for the Six Months Ended 30 June 2008

Drug R&D Division: New employee share option scheme in Hutchison MediPharma

Notice of 2008 Interim Results

Blocklisting Six Monthly Return

Director's Shareholding

Board Change

China Healthcare Division Chi-Med increases ownership of its Hutchison Healthcare joint venture

Expansion of Consumer Products division Sen launches in 125 Marionnaud beauty stores

Results of Annual General Meeting

Holding in Company

Annual Report 2007 and Notice of Annual General Meeting

Holding in Company

Preliminary Results for the year ended 31 December 2007

Chi-Med Announces Start of Patient Enrolment in a Global Phase IIb Ulcerative Colitis Clinical Trial of HMPL-004, its Leading Anti-Inflammatory Drug Candidate

Notice of 2007 Preliminary Results

Change in the Registered Office Address in the Cayman Islands

Strong growth in China Healthcare divisionStreamlining of product range set to further improve financial performance

Block Admission Return

Chi-Med Plans to Initiate Global Phase IIb Trials of its Lead Anti-Inflammatory Drug Candidate, HMPL-004, in Ulcerative Colitis Patients

和黃醫藥與美國禮來簽訂新藥研發戰略合作協議

Interim Results for the Six Months Ended 30 June 2007

Notice of Interim Results

Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis

Block Admission

Chi-Med locks-in property gain and protects low cost R&D structure through acquisition of Shanghai facility

Chi-Med completes patient enrolment on its HMPL-004 ulcerative colitis proof-of-concept; Phase II clinical trial in China

Director's Shareholding

Results of Annual General Meeting

Annual Report and Accounts 2006 - Notice of Annual General Meeting

Board Change

Director's Shareholding

Preliminary Results for the year ended 31 December 2006

Notice of Preliminary Results

Related party transaction Chi-Med formalises China Sales and Distribution Arrangements

Appointment of Joint Broker

和黃醫藥與默克共同開發新型小分子抗癌藥物